Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid Tumors
This study is ongoing, but not recruiting participants.
Study NCT01311713   Information provided by Teva Pharmaceutical Industries

First Received on March 7, 2011.   Last Updated on March 19, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Solid Tumors
Additional conditions recognized in this trial
Neoplasms
Interventions listed in this trial
CEP-9722
Sponsors listed in this trial
Cephalon


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services